Blontuvetmab (AT 004) is a caninized monoclonal antibody targeting CD20, designed specifically for canine applications. It exhibits dual functionality by acting as a highly potent and selective antagonist of the A2aR receptor while also displaying weak agonistic activity towards the Nociceptin/Orphanin FQ receptor (NOP). This antibody effectively inhibits the activation of A2aR mediated by 5'-N-Ethylcarboxamidoadenosine (NECA), and it significantly counteracts the adenosine-induced suppression of CD8 T cell activation. This action leads to an increase in cytokine production, including IFN-γ. Blontuvetmab is primarily used in research focused on Canine B-cell lymphoma, offering a valuable tool for studying the modulation of immune responses in this condition.
Blontuvetmab (AT 004) is a caninized monoclonal antibody targeting CD20, designed specifically for canine applications. It exhibits dual functionality by acting as a highly potent and selective antagonist of the A2aR receptor while also displaying weak agonistic activity towards the Nociceptin/Orphanin FQ receptor (NOP). This antibody effectively inhibits the activation of A2aR mediated by 5'-N-Ethylcarboxamidoadenosine (NECA), and it significantly counteracts the adenosine-induced suppression of CD8 T cell activation. This action leads to an increase in cytokine production, including IFN-γ. Blontuvetmab is primarily used in research focused on Canine B-cell lymphoma, offering a valuable tool for studying the modulation of immune responses in this condition.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
